BiopharmaTrend.com

Standigm

Standigm

Private company
STANDIGM

Standigm applies cutting-edge AI technologies to drug discovery. AI and biology experts team up to build a real-world AI model for the pharmaceutical industry. We currently focus on predicting new indications for existing drugs, called drug repositioning through the deeply trained AI model with molecular features of drug responses and drug uses. Standigm generated tens of drug candidates for cancers, Parkinson’s disease (PD), autism, fatty liver diseases (NASH) and more. We promise practical benefits on time and cost in pharmaceutical industry by eliminating some of the uncertainty in the drug discovery process.


Founded
2015
Status
Private company
Geography
South Korea based
Funding
$15.190 M
Patents
1

Products

No products posted yet

Services

No services posted yet


This data is part of our proprietary analytics report:

This service is currently only supported on the desktop screens, please, use this service from your desktop or laptop for correct visualization and functionality

Go to home page